FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2006063886> ?p ?o ?g. }

• W2006063886 endingPage "1470" @default.
• W2006063886 startingPage "1467" @default.
• W2006063886 abstract "No AccessJournal of UrologyCLINICAL UROLOGY: Original Articles1 Apr 2004ADJUVANT CHEMOTHERAPY WITH PACLITAXEL AND CARBOPLATIN IN PATIENTS WITH ADVANCED BLADDER CANCER: A STUDY BY THE HELLENIC COOPERATIVE ONCOLOGY GROUP A. BAMIAS, Ch. DELIVELIOTIS, G. ARAVANTINOS, Ch. KALOFONOS, A. KARAYIANNIS, and M.A. DIMOPOULOS A. BAMIASA. BAMIAS More articles by this author , Ch. DELIVELIOTISCh. DELIVELIOTIS More articles by this author , G. ARAVANTINOSG. ARAVANTINOS More articles by this author , Ch. KALOFONOSCh. KALOFONOS More articles by this author , A. KARAYIANNISA. KARAYIANNIS More articles by this author , and M.A. DIMOPOULOSM.A. DIMOPOULOS More articles by this author View All Author Informationhttps://doi.org/10.1097/01.ju.0000118956.96871.18AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: Radical cystectomy represents the treatment of choice for muscle infiltrative bladder carcinoma. Adjuvant chemotherapy has been used to improve outcome after cystectomy. We report results in a prospective cohort of patients at high risk for relapse who were treated with the combination of paclitaxel and carboplatin as adjuvant treatment following cystectomy for muscle invasive bladder cancer. Materials and Methods: A total of 92 patients with extravesical tumor extension (pT 3b or greater) or lymph node involvement (N+) were treated with 4 cycles of paclitaxel at 175 mg/m2 and carboplatin (area under the curve 5 according to the Calvert formula) every 3 weeks following radical cystectomy. Patients were followed every 6 months thereafter. Results: Median followup was 36.6 months. Chemotherapy was well tolerated with 62% of patients receiving 100% of the expected chemotherapy doses without delays. Grade 3 or 4 neutropenia was reported in 19% of patients, while neutropenic fever was reported in 7%. Five-year overall, cause specific and disease-free survival was 28.9% (95% CI 14.8 to 43.0), 36.6% (95% CI 24.4 to 49.7) and 29% (95% CI 16.3 to 42.4), respectively. Conclusions: Adjuvant chemotherapy with paclitaxel and carboplatin is feasible and could be used as adjuvant treatment for high risk bladder carcinoma. Its true value should be assessed in prospective, randomized trials. References 1 : Uncertainty and outcome in invasive bladder cancer. Urol Oncol1996; 2: 92. Google Scholar 2 : The role of systemic chemotherapy in the management of muscle-invasive bladder cancer. Lancet Oncol2002; 3: 738. Google Scholar 3 : The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J Urol1991; 145: 459. Link, Google Scholar 4 : Advanced bladder cancer (stages pT3b, pT4a, pN1 and pN2): improved survival after radical cystectomy and 3 adjuvant cycles of chemotherapy. Results of a controlled prospective study. J Urol1992; 148: 302. Link, Google Scholar 5 : Adjuvant cisplatin chemotherapy following cystectomy for bladder cancer: results of a prospective randomized trial. J Urol1994; 152: 81. Link, Google Scholar 6 : A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer. J Urol1996; 155: 495. Link, Google Scholar 7 : Adjuvant chemotherapy in locally advanced bladder cancer: final analysis of a controlled multicentre study. Acta Urol Ital1997; 11: 5. Google Scholar 8 : Role of adjuvant chemotherapy in the treatment of invasive carcinoma of the urinary bladder. J Clin Oncol1998; 16: 1601. Google Scholar 9 : Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group. J Clin Oncol1994; 12: 2264. Google Scholar 10 : Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J Clin Oncol1997; 15: 1853. Google Scholar 11 : Carboplatin and urothelial tumors. Oncology1993; 50: 28. Google Scholar 12 : Paclitaxel plus carboplatin in advanced carcinoma of the urothelium: an active and tolerable outpatients regimen. J Clin Oncol1998; 16: 255. Google Scholar 13 : Phase II trial of paclitaxel and carboplatin in the treatment of advanced urothelial carcinoma. J Clin Oncol1998; 16: 1844. Google Scholar 14 : Non-parametric estimation for incomplete observations. J Am Stat Assoc1958; 53: 457. Google Scholar 15 : Controversies in neoadjuvant and adjuvant chemotherapy for muscle-invasive urothelial cancer and clinical research initiatives in locally advanced disease. In: ASCO Educational Book. Alexandria, Virginia: American Society of Clinical Oncology2003: 478. Google Scholar 16 : Chemotherapy in the post-MVAC era: the case for adjuvant chemotherapy. World J Urol2002; 20: 144. Google Scholar 17 : Adjuvant cyclophosphamide, doxorubicin, and cisplatin chemotherapy for bladder cancer: an update. J Clin Oncol1998; 6: 1590. Google Scholar 18 : The role of adjuvant combination chemotherapy after cystectomy in locally advanced bladder cancer: what we do not know and why. Ann Oncol2000; 11: 851. Google Scholar 19 : Adjuvant methotrexate, vinblastine and cisplatin chemotherapy for invasive transitional cell carcinoma: Taiwan experience. J Urol1996; 155: 118. Link, Google Scholar 20 : The role of radiation therapy in the management of transitional cell carcinoma of the bladder. Hematol Oncol Clin North Am1992; 6: 147. Google Scholar From the Departments of Clinical Therapeutics and Urology, University of Athens, School of Medicine (AB, CD, AK, MAD) and Medical Oncology Department, Agii Anargyri (GA), Athens and Department of Internal Medicine, University of Patra, School of Medicine (CK), Rio, Greece© 2004 by American Urological Association, Inc.FiguresReferencesRelatedDetails Volume 171Issue 4April 2004Page: 1467-1470 Advertisement Copyright & Permissions© 2004 by American Urological Association, Inc.Keywordsbladder neoplasmscarboplatinchemotherapy, adjuvantpaclitaxelbladderMetricsAuthor Information A. BAMIAS More articles by this author Ch. DELIVELIOTIS More articles by this author G. ARAVANTINOS More articles by this author Ch. KALOFONOS More articles by this author A. KARAYIANNIS More articles by this author M.A. DIMOPOULOS More articles by this author Expand All Advertisement PDF downloadLoading ..." @default.
• W2006063886 created "2016-06-24" @default.
• W2006063886 creator A5017011213 @default.
• W2006063886 creator A5033573338 @default.
• W2006063886 creator A5039349296 @default.
• W2006063886 creator A5041797266 @default.
• W2006063886 creator A5047544017 @default.
• W2006063886 creator A5051493120 @default.
• W2006063886 date "2004-04-01" @default.
• W2006063886 modified "2023-10-13" @default.
• W2006063886 title "ADJUVANT CHEMOTHERAPY WITH PACLITAXEL AND CARBOPLATIN IN PATIENTS WITH ADVANCED BLADDER CANCER: A STUDY BY THE HELLENIC COOPERATIVE ONCOLOGY GROUP" @default.
• W2006063886 cites W13718780 @default.
• W2006063886 cites W1426844501 @default.
• W2006063886 cites W1439606022 @default.
• W2006063886 cites W1858135205 @default.
• W2006063886 cites W189060137 @default.
• W2006063886 cites W1936664258 @default.
• W2006063886 cites W1939723756 @default.
• W2006063886 cites W1954311312 @default.
• W2006063886 cites W1957837469 @default.
• W2006063886 cites W2007006095 @default.
• W2006063886 cites W2082683904 @default.
• W2006063886 cites W2095168415 @default.
• W2006063886 cites W2142588948 @default.
• W2006063886 cites W2146102224 @default.
• W2006063886 cites W2257014360 @default.
• W2006063886 cites W2400606016 @default.
• W2006063886 cites W3041047318 @default.
• W2006063886 cites W4300795463 @default.
• W2006063886 doi "https://doi.org/10.1097/01.ju.0000118956.96871.18" @default.
• W2006063886 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15017199" @default.
• W2006063886 hasPublicationYear "2004" @default.
• W2006063886 type Work @default.
• W2006063886 sameAs 2006063886 @default.
• W2006063886 citedByCount "18" @default.
• W2006063886 countsByYear W20060638862012 @default.
• W2006063886 countsByYear W20060638862014 @default.
• W2006063886 countsByYear W20060638862022 @default.
• W2006063886 crossrefType "journal-article" @default.
• W2006063886 hasAuthorship W2006063886A5017011213 @default.
• W2006063886 hasAuthorship W2006063886A5033573338 @default.
• W2006063886 hasAuthorship W2006063886A5039349296 @default.
• W2006063886 hasAuthorship W2006063886A5041797266 @default.
• W2006063886 hasAuthorship W2006063886A5047544017 @default.
• W2006063886 hasAuthorship W2006063886A5051493120 @default.
• W2006063886 hasConcept C121608353 @default.
• W2006063886 hasConcept C126322002 @default.
• W2006063886 hasConcept C126894567 @default.
• W2006063886 hasConcept C143998085 @default.
• W2006063886 hasConcept C2775910329 @default.
• W2006063886 hasConcept C2776694085 @default.
• W2006063886 hasConcept C2777292972 @default.
• W2006063886 hasConcept C2778239845 @default.
• W2006063886 hasConcept C2780258809 @default.
• W2006063886 hasConcept C2780352672 @default.
• W2006063886 hasConcept C2780849966 @default.
• W2006063886 hasConcept C2781451048 @default.
• W2006063886 hasConcept C71924100 @default.
• W2006063886 hasConceptScore W2006063886C121608353 @default.
• W2006063886 hasConceptScore W2006063886C126322002 @default.
• W2006063886 hasConceptScore W2006063886C126894567 @default.
• W2006063886 hasConceptScore W2006063886C143998085 @default.
• W2006063886 hasConceptScore W2006063886C2775910329 @default.
• W2006063886 hasConceptScore W2006063886C2776694085 @default.
• W2006063886 hasConceptScore W2006063886C2777292972 @default.
• W2006063886 hasConceptScore W2006063886C2778239845 @default.
• W2006063886 hasConceptScore W2006063886C2780258809 @default.
• W2006063886 hasConceptScore W2006063886C2780352672 @default.
• W2006063886 hasConceptScore W2006063886C2780849966 @default.
• W2006063886 hasConceptScore W2006063886C2781451048 @default.
• W2006063886 hasConceptScore W2006063886C71924100 @default.
• W2006063886 hasIssue "4" @default.
• W2006063886 hasLocation W20060638861 @default.
• W2006063886 hasLocation W20060638862 @default.
• W2006063886 hasOpenAccess W2006063886 @default.
• W2006063886 hasPrimaryLocation W20060638861 @default.
• W2006063886 hasRelatedWork W192472069 @default.
• W2006063886 hasRelatedWork W2081749499 @default.
• W2006063886 hasRelatedWork W2092515994 @default.
• W2006063886 hasRelatedWork W2138113364 @default.
• W2006063886 hasRelatedWork W2164332056 @default.
• W2006063886 hasRelatedWork W2375370454 @default.
• W2006063886 hasRelatedWork W2395412721 @default.
• W2006063886 hasRelatedWork W2417982295 @default.
• W2006063886 hasRelatedWork W2419621113 @default.
• W2006063886 hasRelatedWork W4244439098 @default.
• W2006063886 hasVolume "171" @default.
• W2006063886 isParatext "false" @default.
• W2006063886 isRetracted "false" @default.
• W2006063886 magId "2006063886" @default.
• W2006063886 workType "article" @default.